Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare Diseases
The multi-year partnership launches with focus on epilepsy, rare disease and AISAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE)...
Clinical Trial
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology...
Stemtech Corporation Announces Entry into China in a Joint Venture with Lightway Ventures
NAPLES, FL / ACCESS Newswire / December 2, 2025 / Stemtech Corporation, the global leader and pioneer in stem cell...
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trialsCAMBRIDGE, Mass., Dec....
Cannabix Technologies Strengthens Presence in Maritime Market with Repeat BreathLogix Alcohol Screening Device Order
VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company...
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
~ New U.S. Patent Extends Protection Through 2042 ~~ Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR®...
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease...
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase...
PolarityBio Completes Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development...
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval PathwayPRINCETON, N.J., Dec. 02, 2025 (GLOBE...
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an...
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing...
SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI
FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21...
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that...
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory...
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a...
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports...
Science 37 Receives 2025 Clinical Trials Arena Site Innovation Award for R&D Leadership
MORRISVILLE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today...
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...
Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer
Dr. Quezada-Ruiz, an internationally recognized ophthalmologist and experienced drug development leader, has joined the company as Chief Medical Officer.Seemi Khan,...